Cancer Clinical Trials Results
A First-in-Human Single Ascending Dose Study of TRX518 in Subjects with Unresectable Stage III or Stage IV Malignant Melanoma or other Solid Tumor Malignancies
||Main Campus|| || ||Melanoma, Solid Tumors
A Phase II, Open-label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand
||Main Campus|| ||Phase 2||Melanoma
Phase I/II Study of the Safety and Efficacy of the AKT Inhibitor GSK2141795 in combination with the BRAF inhibitor Dabrafenib in patients with BRAF mutant cancer
||Beachwood, Fairview, Hillcrest, Independence, Main Campus, North Coast Cancer, Strongsville, Wooster|| || ||Melanoma
Cancer Answers & Appointments
Speak with a cancer nurse specialist for appointment assistance and for answers to your questions about cancer locally at 216.444.7923 or toll-free 1.866.223.8100.
Monday through Friday from 8 a.m. – 4:30 p.m. (ET).
Resources for medical professionals
- Outpatient appointment referrals: 216.444.7923 or 866.223.8100
- Inpatient hospital transfers: 800.553.5056
- Referring Physician Concierge: 216.444.6196 or 216.312.4910.
Search available cancer clinical trials by disease, hospital, phase or number.
This information is provided by Cleveland Clinic and is not intended to replace
the medical advice of your doctor or health care provider.
Please consult your health care provider for advice about a specific medical condition.
© Copyright 2015 Cleveland Clinic. All rights reserved.